Gather additional industry and technical information from our repository of resources and educational content.

Filter 172 Results

Modality
Application
Technology
Service
Content Type

Lipid-Based Formulation Technology

Lipid-based formulations (LBF) - including use of lipid excipients, solvents, cosolvents in liquid, semi-solid, or solid formats - are key approaches for improving solubility and bioavailability. This technical brief reviews Lonza's extensive LBF expertise, using liquid-filled hard capsules, soft gels, and lipid multiparticulates to support projects from early design stages through commercialization. To learn more, please see our technical brief.
Publish Date: 05-May-2020

Softgels

This technical brief describes Lonza's unique one-piece softgel capsule technology that can be used to deliver a wide range of formulation types and excipients. These capsules feature an easy-to-swallow shell that meets all global quality standards, as well as a tamper-resistant shell that masks taste and smell. The capsules are available in a wide range of unique shapes and colors to meet branding, line extension, and life-cycle management objectives. To learn more, please read our technical brief.
Publish Date: 05-May-2020

Solid Dosage Manufacturing, Packaging and Distribution

Solid dosage form manufacturing, packaging, and distribution can be key steps in getting products to market. Lonza offers integrated, full-service capabilities in these areas, which can help expedite product development timelines, reduce the risks associated with managing multiple partners, and accelerate speed to clinic and product commercialization. Product design, development, and manufacturing sites worldwide produce a full range of oral dosage forms in current Good Manufacturing Practice (cGMP) environments for clinical and commercial supply. To learn more, please see our technical brief.
Publish Date: 05-May-2020

Spray-Dried Dispersion Technology

With more than 20 years of formulation and manufacturing expertise, Lonza's spray-dried dispersion (SDD) platform incorporations compositions, processes, and dosage forms designed and proven to enhance bioavailability and the delivery of solid dosage forms. To learn more, please see our technical brief.
Publish Date: 05-May-2020

Taste-masking for Enhanced Oral Delivery

Taste-masking technologies offer huge benefits in patient compliance but meeting diverse product specifications in a narrow formulation space can be difficult. This technical brief describes the array of specialized taste-masking technologies and formulation approaches Lonza uses to address the bitter taste of many drugs, combining industry-leading expertise in innovative taste-masking approaches with enabling technologies. To learn more, please read our technical brief.
Publish Date: 05-May-2020

Modified and Targeted Delivery Technologies

Achieving precise drug-delivery profiles can present substantial formulation challenges. This technical brief describes Lonza's numerous specialized technologies for modified and targeted delivery of drug compounds. These technologies can be used alone and with other enabling technologies to modulate the pharmacokinetics of drug compounds and optimize drug performance and therapeutic effect. To learn more, please read our technical brief.
Publish Date: 05-May-2020

Lonza Regulatory Services - Small Molecules

Today timelines for drug development are getting shorter and shorter with 40% of approvals being expedited. In order to keep up with the tempo and stay ahead of competition every link of the chain from research, drug substance/drug product development and manufacturing needs to be in-sync. Timely and proper documentation and communication with the appropriate regulatory authorities can make a difference. To learn more, please read our technical brief.
Authors: John McGuire, Jakob Bonde
Publish Date: 05-May-2020

Oral Multiparticulate Technologies

Multiparticulates offer a number of advantages, including optimized GI tract distribution, predictable gastrointestinal (GI) transit, formulation flexibility, and protection against dose dumping concerns.  Because of their small size, shape and composition, multiparticulates also offer wide flexibility in the choice of manufacturing process and final dosage form. Lonza’s oral multiparticulate technologies enable you to address a broad range of formulation needs.To learn more, please view our technical brief.
Publish Date: 05-May-2020

Particle-Size Engineering Through Micronization

Stability, flowability, dissolution rate, and bioavailability (BA) are all critical performance parameters affected by particle-size distribution. As part of our integrated product development services, Lonza offers premier particle engineering capabilities through micronization, from early-stage design through scale-up to commercial quantities. To learn more, please see our technical brief.
Publish Date: 05-May-2020

Highly Potent Active Pharmaceutical Ingredients (HPAPIs)

With the pharmaceutical industry's focus on oncology and more targeted therapies, the number of highly potent active pharmaceutical ingredients (HPAPIs) in development continues to increase. as does the demand for HPAPI manufacturing capacity. As described in this technical brief, Lonza has more than 20 years experience in the manufacture and handling of HPAPIs. Our expertise, capabilities, manufacturing innovation, and integrated service options are described. To learn more, please read our technical brief.
Publish Date: 05-May-2020